PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc, the leading cloud platform for patient-centered drug development, today announced the hiring of Dr. Pamela Tenaerts as Chief Scientific Officer. Dr. Tenaerts will lead the scientific office at Medable to drive advancement of decentralized research methodologies with evidence-based best practices. Dr. Tenaerts brings more than 30 years of clinical research experience to Medable, most recently as executive director of the Clinical Trials Transformation Initiative (CTTI) at Duke University.
Dr. Tenaerts is one of the leading advocates for innovation in clinical trials, with a unique personal background as a clinical trials investigator, hospital research administrator and academic in both the U.S. and Europe. Dr. Tenaerts joins Medable from Duke, where she led CTTI’s efforts to develop and drive adoption of practices that increase the quality and efficiency of clinical trials. CTTI is a public-private partnership co-founded in 2007 by Duke and the U.S. Food and Drug Administration. It comprises more than 80 member organizations, including government agencies, industry representatives, patient advocacy groups, professional societies, investigator groups, and academic institutions.
Dr. Tenaerts started her career in private practice and the emergency department. Prior to CTTI, Dr. Tenaerts oversaw European operations for CoAxia, a medical device company focused on cerebral ischemia. She received her M.D. from Catholic University of Leuven, Belgium, and an MBA from the University of South Florida. She is on the board of directors for the Society for Clinical Trials, and the Scientific Leadership Board for the Digital Medicine Society (DiME).
“Pam’s leadership will be vital to bringing innovation, evidence and best practices to fuel the future of patient-centered clinical research,” said Dr. Michelle Longmire, CEO and co-founder of Medable. “Pam’s experience in every trial process—seeing traditional trial hurdles first-hand while also having an industry-wide view of how trials are changing—will allow our team and our partners to quickly identify pain points so physicians can focus more on patient needs.”
As Medable’s chief scientific officer, Dr. Tenaerts will lead evidence collection around patient centricity, efficiency and quality in decentralized trials. She will work with Medable’s existing science leaders, including Dr. Ingrid Oakley-Girvan, to expand Medable’s digital biomarkers work with NIH and other partners. She will evolve best practices and bring clinical insight into Medable’s continued work on a master protocol approach to multi-study research. And with more than one million participants currently on the Medable platform, Dr. Tenaerts will create ways to keep participants engaged for potential future clinical trial participation.
“The U.S. is losing the battle against chronic disease, but decentralized trials offer a different path forward,” said Dr. Tenaerts. “Currently, less than 10 percent of Americans participate in research, a number that has been stagnant for years. Decentralizing trials with the Medable platform offers a reality where clinical trials are deployed for many more to participate, and for actionable evidence to be generated reliably, seamlessly and faster than current models.”
Medable experienced record growth in 2020 as the COVID-19 pandemic drove demand for remote clinical trial technologies. By minimizing the need for in-person site visits, Medable customers have achieved unprecedented results – including 3X faster enrollment and over 90 percent retention rates. Medable launched five new products and onboarded more than 50 new clients during the year, growing revenues by more than 400 percent – and fueling $118 million in new funding to accelerate digital and decentralized clinical trial adoption.
For ongoing insight about decentralized trial adoption and patient-centered research, follow Medable via our blog, LinkedIn, Twitter and Facebook channels.
About Medable
Medable is on a mission to get effective therapies to patients faster by transforming clinical drug development with disruptive technologies. The company’s digital platform streamlines design, recruitment, retention and data quality for decentralized trials, replacing siloed systems with integrated digital tools, data and interfaces to accelerate trial execution. Medable connects patients, sites and clinical trial teams to improve patient access, experience, and outcomes. Medable is a privately held, venture-backed company headquartered in Palo Alto, California.
